<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840537</url>
  </required_header>
  <id_info>
    <org_study_id>SFED 131</org_study_id>
    <nct_id>NCT04840537</nct_id>
  </id_info>
  <brief_title>Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis</brief_title>
  <official_title>Comparison of Two Diagnostic Strategies in Indeterminate Biliary Stenosis: Exploration by Retrograde Cholangioscopy From the Outset or After Failure of Conventional Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederic PRAT, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Cochin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biliary stenosis not associated with a mass is difficult to diagnose with certainty. The&#xD;
      diagnosis is usually based on a first-line cytological study of biliary brushing, which&#xD;
      allows a diagnosis in 30 to 50% of cases. In the event of negativity, it is then possible to&#xD;
      perform a cholangioscopy in a second step, which allows better sensitivity by performing&#xD;
      biopsies. Performing cholangioscopy from the start could potentially save time and avoid&#xD;
      disturbances associated with intermediate biliary stenting.&#xD;
&#xD;
      The main objective is to compare two strategies for exploring indeterminate biliary stenosis&#xD;
      (1st vs. 2nd line retrograde cholangioscopy) in terms of diagnostic performance. The&#xD;
      secondary objectives are to compare the same two strategies in terms of effectiveness, side&#xD;
      effects and cost-effectiveness.&#xD;
&#xD;
      The primary outcome measure is the diagnostic yield (performance) of the initial&#xD;
      investigation of indeterminate biliary stenosis: cytological brushing followed by&#xD;
      cholangioscopy in case of failure (control group) or cholangioscopy from the start (study&#xD;
      group).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">December 26, 2022</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield (performance) of the initial investigation of indeterminate biliary stenosis: cytological brushing followed by cholangioscopy in case of failure (control group) or cholangioscopy from the start (study group).</measure>
    <time_frame>48 months</time_frame>
    <description>Diagnostic performance is expressed primarily by sensitivity for the diagnosis of malignancy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific rate of diagnosis with cholangioscopy by spyglass used in 1st or 2nd intention</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events related to diagnostic procedures in each of the 2 groups</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the costs of the 2 diagnostic strategies</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Malignant Biliary Stenosis</condition>
  <arm_group>
    <arm_group_label>cytological brushing followed by cholangioscopy in case of failure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cholangioscopy from the start</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP</intervention_name>
    <description>endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage</description>
    <arm_group_label>cholangioscopy from the start</arm_group_label>
    <arm_group_label>cytological brushing followed by cholangioscopy in case of failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of intra- or extrahepatic biliary stenosis, involving the main bile ducts:&#xD;
             common hepatic duct, right and left hepatic ducts&#xD;
&#xD;
          -  Presence of clinical jaundice and / or biological cholestasis (GGT&gt; 3N)&#xD;
&#xD;
          -  Absence of visible mass near the biliary stenosis after initial morphological&#xD;
             assessment by abdominal CT scan, MRI with biliary sequences.&#xD;
&#xD;
          -  Endoscopic ultrasound performed and not having allowed the acquisition of material of&#xD;
             diagnostic interest by guided puncture of the lesion.&#xD;
&#xD;
          -  No history of ERCP in the 6 months preceding inclusion and no biliary prosthesis&#xD;
             (plastic or metal) in place at the time of inclusion&#xD;
&#xD;
          -  Collegial validation of the need for a formal diagnosis of indeterminate biliary&#xD;
             stenosis in order to guide therapeutic management&#xD;
&#xD;
          -  Patients aged 18 to 85&#xD;
&#xD;
          -  Patient who gave his consent to participate in the study&#xD;
&#xD;
          -  No contraindication to anesthesia (ASA 1, 2,3)&#xD;
&#xD;
          -  Patient affiliated to a social security scheme (beneficiary or beneficiary)&#xD;
&#xD;
          -  Absence of pregnancy and current contraception in women of childbearing age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a manifest tissue mass in relation to the biliary stenosis on CT and / or&#xD;
             MRI imaging.&#xD;
&#xD;
          -  Very strong presumption of the etiological diagnosis of biliary stenosis given the&#xD;
             history (history, background): i.e. liver surgery, cholecystectomy, autoimmunity&#xD;
&#xD;
          -  History of ERCP and / or percutaneous biliary drainage in the 6 months preceding&#xD;
             inclusion&#xD;
&#xD;
          -  Presence of a plastic or metal biliary prosthesis in place at the time of inclusion&#xD;
&#xD;
          -  History of cephalic duodeno-pancreatectomy or hepatico-jejunal anastomosis&#xD;
&#xD;
          -  Non-passable stenosis of the main bile duct&#xD;
&#xD;
          -  Severe coagulopathy, thrombocytopenia &lt;75,000 G / L, treatment with clopidogrel cannot&#xD;
             be interrupted even temporarily&#xD;
&#xD;
          -  Anesthetic contraindication (ASA 4)&#xD;
&#xD;
          -  Inability to obtain informed consent&#xD;
&#xD;
          -  person deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frederic Prat, MD, PhD</last_name>
    <phone>+33 (0)140875663</phone>
    <email>frederic.prat@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Lorenzo, MD</last_name>
    <email>diane.lorenzo@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>frederic prat, MD, PhD</last_name>
      <phone>+33 (0)140875663</phone>
      <email>maximilien.barret@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Cochin</investigator_affiliation>
    <investigator_full_name>Frederic PRAT, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investagator, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>biliary stenosis</keyword>
  <keyword>cholangioscopy</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>ERCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

